(Bloomberg) — Education technology company Udemy Inc. fell 5.2% on its first day as a public company, a bottom-of-the-class debut in a banner year for U.S. listings.
Most Read from Bloomberg
Into the Metaverse: Where Crypto, Gaming and Capitalism Collide
Can a New Mayor Fix Seattle’s Downtown?
The Terrifying Rise of Haunted Tourism
The Best New Restaurants in Washington, Chosen by Top Chefs
In Minneapolis Election, the Future of Policing Is at Stake
Shares of the San Francisco-based Udemy, which sold for $29 in the IPO, closed at $27.50 in New York trading Friday, giving the company a market value of about $3.8 billion.
Udemy sold 14.5 million shares Thursday at the top of a marketed range of $27 to $29 to raise $421 million. Accounting for employee stock options, the company has a fully diluted value of more than $4.3 billion. The company was valued at $3.3 billion in a private investment last year, according to data provider PitchBook.
In a year in which IPOs have eclipsed previous records, Udemy’s is one of only 34 out of almost 200 listings of $200 million or more in which the stock closed on the first day below the offer price, according to data compiled by Bloomberg. Udemy ranked 25th worst of those, excluding blank-check companies, the data show.
Insight’s Stake
Udemy’s biggest investor is Insight Partners, which with its affiliates owns more than 30% of the company’s shares after the listing. Other top shareholders, according to Udemy’s filings with the U.S. Securities and Exchange Commission, include MIH Edtech Investments, which is a unit of Prosus NV, and Norwest Venture Partners.
Udemy’s revenue for the first six months of the year was $251 million, up from $201 million the year before. Its net loss narrowed to $29 million from $52 million a year ago.
Udemy provides online video courses across a variety of categories, including web development, marketing and business. The company said it had more than 201 million course enrollments last year with over 44 million users globally.
Its corporate customers include Citigroup Inc., Jaguar Land Rover, PayPal Holdings Inc. and Box Inc.
Coursera, Pluralsight
In the risk-factors section of the prospectus, Udemy acknowledges that it’s in a highly competitive market which includes Coursera Inc., Pluralsight Inc. and LinkedIn Learning.
Morgan Stanley and JPMorgan Chase & Co. led the offering. The company’s shares are trading on the Nasdaq Global Select Market under the symbol UDMY.
(Updates with closing share price in second paragraph)
Most Read from Bloomberg Businessweek
The Slip-and-Fall King Wants to Save You From Your Next Wipeout
Australia Braces for Life After Covid Zero
Big Teacher Is Watching: How AI Spyware Took Over Schools
Workers Press for Power in Rare Advance for U.S. Labor Movement
You Could Be Competing With Bots to Buy Gifts This Christmas
©2021 Bloomberg L.P.
In this article, we discuss the 10 dividend stocks with over 10% yield. If you want to skip our detailed analysis of these stocks, go directly to the 5 Dividend Stocks With Over 10% Yield. The Federal Reserve Bank of Dallas recently forecast that home prices and rent are likely to rise in the coming […]
Peloton's stock gets pounded after a lackluster quarter and outlook. Here's why one analyst thinks it's time to buy.
What happened Shares of BioNTech (NASDAQ: BNTX) were plunging 19.8% as of 11:12 a.m. EDT on Friday. The steep decline came after Pfizer (NYSE: PFE) announced positive results from a late-stage study of its experimental COVID-19 pill Paxlovid.
A competitor's luxury sedan is getting phenomenal reviews, and Nio investors are getting nervous.
Shares of Moderna (NASDAQ: MRNA) fell on Friday, following a major development in the war against COVID-19. Rival drugmaker Pfizer (NYSE: PFE) announced that its clinical study results indicate that its investigational antiviral treatment could slash the risk of hospitalization or death by 89% in non-hospitalized adults with COVID-19. "Today's news is a real game-changer in the global efforts to halt the devastation of this pandemic," Pfizer CEO Albert Bourla said in a press release.
If you look beyond the hottest tickers, you can find companies giving out jumbo dividends.
Shares of Merck & Co. tumbled 9.5% in midday trading Friday, putting them on track to suffer the biggest one-day drop since January 2005, after Pfizer Inc. released data on a pill to treat COVID-19 that showed greater efficacy than Merck's. The stock's price decline of $8.61 was shaving about 57 points off the Dow Jones Industrial Average's price, while the Dow rallied 246 points, or 0.7%. The stock's big selloff, the stock has retraced about 56% of the gain, from the Sept. 29 close of $75.11 to
State-owned Bauhinia Culture (Hong Kong) Holdings Ltd is eying to acquire Alibaba Group Holding Ltd's (NYSE: BABA) owned South China Morning Post English-language newspaper, Bloomberg reports. Founded in 1903, SCMP was once one of the most profitable newspapers globally, boosted by a large classified job-advertisement section. Media mogul Rupert Murdoch acquired control of SCMP in 1986 before selling his stake to Malaysian tycoon Robert Kuok in 1993. SCMP changed hands again in 2015 when Alibaba
Rivian Automotive boosted the price range for its much anticipated initial public offering on Friday, less than a week before its shares will begin trading. Rivian plans to trade on the Nasdaq under the ticker RIVN. Morgan Stanley, Goldman Sachs, and J.P. Morgan are the lead underwriters on the deal.
Often acclaimed as “the Steve Jobs of Investing,” Ray Dalio is an investment expert whose tough-but-innovative management style has revolutionized how to analyze stocks to buy. Dalio founded Bridgewater Associates in 1975, now one of the most successful hedge funds out there with over $200 billion in assets under management (AUM). This ace investor employs a simple three-step formula: save money, create a diversified portfolio and understand the market’s long-term cycles. During times of volatil
Chipmaker Nvidia is making waves with its technology to create enterprise metaverse applications. On Tuesday, the Santa Clara, Calif.-based company likely will announce the general availability of Omniverse Enterprise, Wells Fargo analyst Aaron Rakers said in a note to clients. The news is expected to break during a keynote presentation from Nvidia Chief Executive Jensen Huang at the start of the company's virtual GTC conference.
See who joins FB, MSFT stock on this screen of Warren Buffett stocks based on the investing strategy of the Berkshire Hathaway CEO.
The price of Bitcoin keeps rising. A number of Bitcoin stocks — or companies that have business tied to the cryptocurrency — have followed suit. But given the on-a-whim price swings in the crypto world, finding the best stocks out of that bunch can be difficult. For now, based on IBD's analysis, the best crypto stocks and Bitcoin stocks to…
Semiconductor stocks are hopping again. This past week saw a bunch of chip stocks breaking out of bases and racing to all-time highs.
Top digital payments stock PayPal is one of the leading growth stocks in the current stock market. But is it a buy right now?
Warren Buffett got schooled during the pandemic. And now it's Nvidia's turn to pass up Buffett's Berkshire Hathaway.
In this article, we discuss the 10 best fuel stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Fuel Stocks To Buy Now. Oil stocks have consistently underperformed the benchmark S&P 500 in the past two years, due in large part to the […]
Shares of CrowdStrike Holdings (NASDAQ: CRWD) rose 14.7% in October after the company announced a number of new products and partnerships. The cybersecurity company held an investor product briefing on Oct. 12, at which it announced its expanded and updated offering. CrowdStrike is averaging close to 100% annual revenue growth, and it's now considered a global leader in endpoint security services for businesses.
Many are trying to find alternative, non-correlated asset classes that can generate bond-like returns without the interest-rate and credit risk.
Is Moderna stock a buy or a sell as it takes a beating in November on a myriad of challenges facing its Covid vaccine?
